Search clinical trials for: INSULIN GLARGINE (U300)

Total 4023 results

Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Eli Lilly and Company

Completed

A Study in Participants With Type 1 Diabetes Mellitus (IMAGINE 1)

Diabetes Mellitus, Type 1

Japan, United States, Russian Federation, France, Mexico, Austria, Germany, Italy, Poland
Novo Nordisk A/S

Completed

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)

Type 2 Diabetes Mellitus

United States, Hungary, Puerto Rico, Spain, Australia, Korea, Republic of, Mexico, Japan, Germany, Russian Federation, Taiwan, Slovakia, Argentina, Czechia, India, Italy
Eli Lilly and Company

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Diabetes Mellitus, Type 2

Turkey, Argentina, Korea, Republic of, Brazil, China, Egypt, India, Spain
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Germany, Switzerland
Mayo Clinic
Arizona State University

Terminated

Molecular Regulation of Muscle Glucose Metabolism

Obesity | Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes

Italy
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes (AWARD-CHN3)

Type 2 Diabetes Mellitus

China
CPEX Pharmaceuticals Inc.

Completed

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus (CPEX-011)

Type 2 Diabetes

United States
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) (IOPE)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Brazil, Canada
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

Diabetes Mellitus, Type 2

United States, Puerto Rico
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
IKFE Institute for Clinical Research and Development

Completed

Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes

Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation, Ukraine
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Population Health Research Institute
AstraZeneca

Completed

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Type 2 Diabetes Mellitus

Canada
Nanjing First Hospital, Nanjing Medical University

Recruiting

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
CPEX Pharmaceuticals Inc.

Withdrawn

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Completed

An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Emory University
Merck Sharp & Dohme LLC; University of Michigan; Temple University; Ohio University

Completed

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Geropharm

Completed

Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients

Diabetes Mellitus | Diabetes Mellitus, Type 1

Russian Federation
Novo Nordisk A/S

Completed

Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt, Morocco, Indonesia, Tunisia, Vietnam
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes (4T)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Ireland
Novo Nordisk A/S

Completed

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

Diabetes Mellitus, Type 2 | Diabetes

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents

Diabetes Mellitus, Type 2 | Diabetes

Indonesia
Novo Nordisk A/S

Completed

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Netherlands, United Kingdom

3

Subscribe